Source:http://linkedlifedata.com/resource/pubmed/id/20684598
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
15
|
pubmed:dateCreated |
2010-8-5
|
pubmed:abstractText |
The hematopoietic prostaglandin D(2) synthase has a proinflammatory effect in a range of diseases, including allergic asthma, where its product prostaglandin D(2) (PGD(2)) has a role in regulating many of the hallmark disease characteristics. Here we describe the development and characterization of a novel series of hematopoietic prostaglandin D(2) synthase inhibitors with potency similar to that of known inhibitors. Compounds N-benzhydryl-5-(3-hydroxyphenyl)thiophene-2-carboxamide (compound 8) and N-(1-amino-1-oxo-3-phenylpropan-2-yl)-6-(thiophen-2-yl)nicotinamide (compound 34) demonstrated low micromolar potency in the inhibition of the purified enzyme, while only 34 reduced Toll-like receptor (TLR) inducible PGD(2) production in both mouse primary bone marrow-derived macrophages and the human megakaryocytic cell line MEG-01S. Importantly, 34 demonstrated a greater selectivity for inhibition of PGD(2) synthesis versus other eicosanoids that lie downstream of PGH(2) (PGE(2) and markers of prostacyclin (6-keto PGF(1alpha)) and thromboxane (TXB(2))) when compared to the known inhibitors HQL-79 (compound 1) and 2-phenyl-5-(1H-pyrazol-3-yl)thiazole (compound 2). Compound 34 therefore represents a selective hematopoietic prostaglandin D(2) synthase inhibitor.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Intramolecular Oxidoreductases,
http://linkedlifedata.com/resource/pubmed/chemical/Ligands,
http://linkedlifedata.com/resource/pubmed/chemical/Lipocalins,
http://linkedlifedata.com/resource/pubmed/chemical/Niacinamide,
http://linkedlifedata.com/resource/pubmed/chemical/Thiophenes,
http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptors,
http://linkedlifedata.com/resource/pubmed/chemical/prostaglandin R2 D-isomerase
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1520-4804
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:day |
12
|
pubmed:volume |
53
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5536-48
|
pubmed:meshHeading |
pubmed-meshheading:20684598-Animals,
pubmed-meshheading:20684598-Cells, Cultured,
pubmed-meshheading:20684598-Crystallography, X-Ray,
pubmed-meshheading:20684598-Hematopoiesis,
pubmed-meshheading:20684598-Humans,
pubmed-meshheading:20684598-Intramolecular Oxidoreductases,
pubmed-meshheading:20684598-Ligands,
pubmed-meshheading:20684598-Lipocalins,
pubmed-meshheading:20684598-Macrophages,
pubmed-meshheading:20684598-Megakaryocytes,
pubmed-meshheading:20684598-Mice,
pubmed-meshheading:20684598-Models, Molecular,
pubmed-meshheading:20684598-Niacinamide,
pubmed-meshheading:20684598-Protein Binding,
pubmed-meshheading:20684598-Structure-Activity Relationship,
pubmed-meshheading:20684598-Thiophenes,
pubmed-meshheading:20684598-Toll-Like Receptors
|
pubmed:year |
2010
|
pubmed:articleTitle |
Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases.
|
pubmed:affiliation |
Institute for Molecular Bioscience, The University of Queensland, Queensland, Australia.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|